# A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015

> **NCT05022771** · PHASE1 · COMPLETED · sponsor: **Pulmongene Ltd.** · enrollment: 54 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** PMG1015 Dose 1
- **DRUG:** PMG1015 Dose 2
- **DRUG:** PMG1015 Dose 3
- **DRUG:** PMG1015 Dose 4
- **DRUG:** PMG1015 Dose 5
- **DRUG:** PMG1015 Dose 6
- **DRUG:** Placebo
- **DRUG:** PMG1015 Dose 7

## Key facts

- **NCT ID:** NCT05022771
- **Lead sponsor:** Pulmongene Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-14
- **Primary completion:** 2022-08-18
- **Final completion:** 2022-08-18
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2023-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05022771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05022771, "A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05022771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*